John L Green's most recent trade in Cogent Biosciences Inc was a trade of 77,000 Common Stock done at an average price of $38.7 . Disclosure was reported to the exchange on Dec. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cogent Biosciences Inc | John L. Green | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 38.68 per share. | 26 Dec 2025 | 77,000 | 131,834 (0%) | 0% | 38.7 | 2,978,360 | Common Stock |
| Cogent Biosciences Inc | John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 300,000 | 353,841 (1%) | 1% | 0 | Common Stock | |
| Cogent Biosciences Inc | John L. Green | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.45 per share. | 17 Dec 2025 | 145,007 | 208,834 (0%) | 0% | 39.4 | 5,720,526 | Common Stock |
| Cogent Biosciences Inc | John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2025 | 50,000 | 53,841 (0%) | 0% | 0 | Common Stock | |
| Cogent Biosciences Inc | John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 270,000 | 270,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Green L. John | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | John L. Green | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.86 per share. | 26 Apr 2021 | 17,813 | 3,841 (0%) | 0% | 8.9 | 157,823 | Common Stock |
| Cogent Biosciences Inc | John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 524 | 21,654 (0%) | 0% | 0 | Common Stock | |
| Cogent Biosciences Inc | John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 270,746 | 270,746 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | John L. Green | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 111,300 | 111,300 | - | - | Stock Option (Right to Buy) |